Bli medlem
Bli medlem

Du är här

2016-02-24

Immune Pharmaceuticals: Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues

IMMUNE PHARMACEUTICALS ANNOUNCES PUBLICATION OF NEW DATA ON EOTAXIN-1 IN
IBD; PATIENT ENROLLMENT IN PHASE II UC TRIAL CONTINUES

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage
biopharmaceutical company, announces publication of new data on the role of
eotaxin-1 in Ulcerative Colitis (UC) and Crohn's Disease (CD). The article,
published in Digestive Disease Science1, presents results of an
observational clinical study intended to characterize serum and intestinal
wall eotaxin-1 levels in inflammatory bowel disease (IBD) patients, and
explores the effect of targeting eotaxin-1 by specific antibodies in an
animal IBD model. These studies were conducted under the oversight of
Professor Goldin, Chairman of the Digestive Diseases Institute at Shaare
Zedek Medical Center of the Hebrew University School of Medicine in
Jerusalem, and supported in part by an unrestricted grant from Immune.

Professor Goldin, the principal investigator for the study, stated: "The
observational clinical study shows that tissue eotaxin-1 correlates with
disease severity in both UC and CD. Additionally, the classic DSS-mouse IBD
model demonstrated that administration of anti-eotaxin-1 resulted in
improvement in the inflammation and disease course of these mice. Professor
Goldin continued "We believe that the results obtained in the clinical
study support the role of eotaxin-1 as a target in IBD, a therapeutic area
in which over half of patients fail to sustain remission. A first-in-class
alternative to currently available therapies will offer a new treatment
option.

"There is room for improvement in treatment of IBD and maintenance of
response," said Dr. Monica Luchi, Immune's Chief Medical Officer and EVP
Global Drug Development. "Immune's goal is to focus on improving patient
outcomes in this devastating illness. With bertilimumab, our eotaxin-1
inhibitor, patients who would be likely to respond based on eotaxin levels
could be selected for treatment through precision medicine, either as first
line biologic or in non-responders to current biologic standard of care.
Our Phase 2a clinical study in Ulcerative Colitis continues to enroll, and
we hope to have patient data by the end of 2016."

Bertilimumab phase 2a double blind placebo controlled trial plans to enroll
42 patients with moderate to severe UC and high tissue eotaxin-1 levels.
Immune filed a patent in 2013 for anti-eotaxin-1 monoclonal antibodies for
the treatment of UC and CD.

1Adar, T., Shteingart, S., Ben-Ya'acov, A., Bar-Gill Shitrit, A., Livovsky
D. M., Shmorak, S., Mahamid, M., Melamud, B., Vernea, F. and Goldin E.
(2016) The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel
Disease: New Insights and Possible Therapeutic Implications. Digestive
Disease Science; Online Publication, 13 February 2016 (DOI
10.1007/S10620-016-4047-z).

NEW YORK, Feb. 24, 2016

For further information: Danielle Shapira, Manager, Strategic Planning,
IMMUNE Pharmaceuticals Inc., 646.440.9327,
danielle.shapira@immunepharma.com

The following documents can be retrieved from beQuoted
Immune Pharmaceuticals Pressrelease 2016-02-24.pdf

About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to
treating and developing novel, highly targeted antibody therapeutics to
improve the lives of patients with inflammatory diseases and cancer.
Immune's oncology pipeline includes Ceplene®, Azixa® and Crolibulin® as
well as bispecific antibodies and nanotherapeutics, including NanomAbs.
Immune's lead product candidate, bertilimumab, is in phase II clinical
development for moderate-to-severe ulcerative colitis as well as for
bullous pemphigoid, an orphan autoimmune dermatological condition. Other
indications being considered for development include atopic dermatitis,
Crohn's disease, severe asthma and NASH (an inflammatory liver disease).
Immune recently expanded its portfolio in immuno-dermatology with topical
nano-formulated cyclosporine-A for the treatment of psoriasis and atopic
dermatitis. Immune's non-core pipeline includes AmiKet™, a late clinical
stage drug candidate for the treatment of neuropathic pain. For more
information, visit Immune's website at
, the content of which is not a part
of this press release.

Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. You are urged to consider statements that include the words
"may," "will," "would," "could," "should," "believes," "estimates,"
"projects," "potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of those words
or other comparable words to be uncertain and forward-looking. Such
forward-looking statements include statements that express plans,
anticipation, intent, contingency, goals, targets, future development and
are otherwise not statements of historical fact. These statements are based
on our current expectations and are subject to risks and uncertainties that
could cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. Factors that may cause actual results or
developments to differ materially include, but not limited to: the risks
associated with the adequacy of our existing cash resources and our ability
to continue as a going concern; the risks associated with our ability to
continue to meet our obligations under our existing debt agreements; the
risk that clinical trials for bertilimumab or AmiKet will not be
successful; the risk that bertilimumab, AmiKet or compounds arising from
our NanomAbs program will not receive regulatory approval or achieve
significant commercial success; the risk that we will not be able to find a
partner to help conduct the Phase III trials for AmiKet on attractive
terms, on a timely basis or at all; the risk that our other product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later-stage
clinical trials; the risk that we will not obtain approval to market any of
our product candidates; the risks associated with dependence upon key
personnel; the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating
losses since our inception; the highly competitive nature of our business;
risks associated with litigation; and risks associated with our ability to
protect our intellectual property. These factors and other material risks
are more fully discussed in our periodic reports, including our reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and
Exchange Commission. You are urged to carefully review and consider the
disclosures found in our filings, which are available at
or at . You are
cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions,
unknown risks or uncertainties or other risk factors. We expressly disclaim
any obligation to publicly update any forward looking statements contained
herein, whether as a result of new information, future events or otherwise,
except as required by law.

SOURCE Immune Pharmaceuticals Inc.

Författare BEQ

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.